MedTrace Logo

S-Equol in Alzheimer's Disease (SEAD) Trial

NCT02142777 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-08-16

No results posted yet for this study

Summary

The purpose of this study is to determine if S-equol could benefit persons with Alzheimer's Disease (AD).

Conditions

Interventions

DRUG

S -Equol

We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.

DRUG

Placebo

The placebo has no active ingredients but is made to look like the study drug.

Sponsors & Collaborators

  • Ausio Pharmaceuticals, LLC

    collaborator INDUSTRY

  • Russell Swerdlow, MD

    lead OTHER

Principal Investigators

  • Russell H Swerdlow, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02142777 on ClinicalTrials.gov